Building Added Value and Trust Through Fuji Pharma Branding

「Fuji Pharma Group has formulated Long-Term Vision 2035 as its vision for ensuring that the cycle of "growth" and "contribution," its management philosophy, continues to generate value over the long term. To realize Long-Term Vision 2035, the Group is pursuing, through its medium-term management plan, 4 growth strategies through the fiscal year ending September 2029: "expanding our contribution to women’s healthcare," "expanding our contribution through the biosimilar business," "contributing earnings through the global CMO business," and "developing and assessing the next growth drivers." These are supported by 3 initiatives to strengthen the management foundation: "strengthening human resources," "enhancing organizational capabilities," and "promoting digitalization."」

「Under these circumstances, the Fuji Pharma Group established Long-Term Vision 2035 as the future state in which it will further circulate its management principles of "Growth" and "Contribution" and continue creating value over the long term. To realize Long-Term Vision 2035, the Group is advancing a medium-term management plan for the next five years comprising four growth strategies, "Expanding our contribution in women's healthcare," "Expanding our contribution through the biosimilars business," "Generating earnings through the global CMO business," and "Laying the groundwork for and identifying the next growth drivers," supported by three initiatives to strengthen the management platform: "Strengthening our people," "Enhancing organizational capabilities," and "Promoting digitalization."」

「Under these circumstances, the Fuji Pharma Group has established a medium-term management plan ending in the fiscal year ending September 2024 as the midpoint for realizing its 2030 Vision: "Contributing to the well-being of women around the world," "Entering the global market from Toyama, the home of medicine," and "Integrating the world's happiest company with social contribution" as the desired state 10 years from now. In the final year of this medium-term management plan, themed "Fujiらしくをあたらしく," the Group is pursuing a growth strategy toward 2030 by strengthening its core areas of women's healthcare and acute care, promoting operations in the ASEAN and North American markets with a sense of urgency, and enhancing its pipeline of new drugs, biosimilars, and generics so that it can expand further over the following five years.」

「Under these circumstances, the Fuji Pharma Group has established a medium-term management plan as a roadmap toward the fiscal year ending September 2024, the midpoint for realizing its 2030 Vision: "Contributing to the well-being of women around the world," "Entering the global market from Toyama, the home of medicine," and "Integrating the world's happiest company with social contribution" as the desired state 10 years from now. Under this medium-term management plan, themed "Fujiらしくをあたらしく," the Group is pursuing a growth strategy toward 2030 by strengthening its core areas of women's healthcare and acute care, actively entering overseas markets such as ASEAN and North America with a sense of urgency, and enhancing its pipeline of new drugs, biosimilars, and generics so that it can expand further over the following five years.」

「Under these circumstances, the Fuji Pharma Group has established a medium-term management plan as a roadmap toward the fiscal year ending September 2024, the midpoint for realizing its 2030 Vision: "Contributing to the well-being of women around the world," "Entering the global market from Toyama, the home of medicine," and "Integrating the world's happiest company with social contribution" as the desired state 10 years from now. Under this medium-term management plan, themed "Fujiらしくをあたらしく," the Group is pursuing a growth strategy toward 2030 by strengthening its core areas of women's healthcare and acute care, actively entering overseas markets such as ASEAN and North America with a sense of urgency, and enhancing its pipeline of new drugs, biosimilars, and generics so that it can expand further over the following five years.」

「Under these circumstances, the Fuji Pharma Group has established a medium-term management plan as a roadmap toward the fiscal year ending September 2024, the midpoint for realizing its 2030 Vision: "Contributing to the well-being of women around the world," "Entering the global market from Toyama, the home of medicine," and "Integrating the world's happiest company with social contribution" as the desired state 10 years from now. Under this medium-term management plan, themed "Fujiらしくをあたらしく," the Group is pursuing a growth strategy toward 2030 by strengthening its core areas of women's healthcare and acute care, actively entering overseas markets such as ASEAN and North America with a sense of urgency, and enhancing its pipeline of new drugs, biosimilars, and generics so that it can expand further over the following five years.」

「Under this medium-term management plan, themed "Fujiらしくをあたらしく," the Group is pursuing a growth strategy toward 2030 by strengthening its core areas of women's healthcare and acute care, actively entering overseas markets such as ASEAN and North America with a sense of urgency, and enhancing its pipeline of new drugs, biosimilars, and generics so that it can expand further over the following five years.」

「Under this medium-term management plan, themed "Fujiらしくをあたらしく," the Group is pursuing a growth strategy toward 2030 by strengthening its core areas of women's healthcare and acute care, actively entering overseas markets such as ASEAN and North America with a sense of urgency, and enhancing its pipeline of new drugs, biosimilars, and generics so that it can expand further over the following five years.」

「Under these circumstances, the Fuji Pharma Group established a new medium-term management plan as a roadmap toward the fiscal year ending September 2024, the midpoint for realizing its 2030 Vision: "Contributing to the well-being of women around the world," "Entering the global market from Toyama, the home of medicine," and "Integrating the world's happiest company with social contribution" as the desired state 10 years from now. Under this medium-term management plan, themed "Fujiらしくをあたらしく," the Group is pursuing a growth strategy toward 2030 by strengthening its core areas of women's healthcare and acute care, actively entering overseas markets such as ASEAN and North America with a sense of urgency, and enhancing its pipeline of new drugs, biosimilars, and generics so that it can expand further over the following five years.」

「Under these circumstances, the Fuji Pharma Group established a new medium-term management plan as a roadmap toward the fiscal year ending September 2024, the midpoint for realizing its 2030 Vision: "Contributing to the well-being of women around the world," "Entering the global market from Toyama, the home of medicine," and "Integrating the world's happiest company with social contribution" as the desired state 10 years from now. Under this medium-term management plan, themed "Fujiらしくをあたらしく," the Group is pursuing a growth strategy toward 2030 by strengthening its core areas of women's healthcare and acute care, actively entering overseas markets such as ASEAN and North America with a sense of urgency, and enhancing its pipeline of new drugs, biosimilars, and generics so that it can expand further over the following five years.」

「A five-year medium-term management plan ending in the fiscal year ending September 2024, titled "Fujiらしくをあたらしく," was established.」

「Under these circumstances, the Fuji Pharma Group established a new medium-term management plan as a roadmap toward the fiscal year ending September 2024, the midpoint for realizing its 2030 Vision: "Contributing to the well-being of women around the world," "Entering the global market from Toyama, the home of medicine," and "Integrating the world's happiest company with social contribution" as the desired state 10 years from now. Under this medium-term management plan, themed "Fujiらしくをあたらしく," the Group is pursuing a growth strategy toward 2030 by strengthening its core areas of women's healthcare and acute care, actively entering overseas markets such as ASEAN and North America with a sense of urgency, and enhancing its pipeline of new drugs, biosimilars, and generics so that it can expand further over the following five years.」

「Under these circumstances, the Fuji Pharma Group established a new medium-term management plan as a roadmap toward the fiscal year ending September 2024, the midpoint for realizing its 2030 Vision: "Contributing to the well-being of women around the world," "Entering the global market from Toyama, the home of medicine," and "Integrating the world's happiest company with social contribution" as the desired state 10 years from now. Under this medium-term management plan, themed "Fujiらしくをあたらしく," the Group is pursuing a growth strategy toward 2030 by strengthening its core areas of women's healthcare and acute care, actively entering overseas markets such as ASEAN and North America with a sense of urgency, and enhancing its pipeline of new drugs, biosimilars, and generics so that it can expand further over the following five years.」

「Under these circumstances, the Fuji Pharma Group established a new medium-term management plan as a roadmap toward the fiscal year ending September 2024, the midpoint for realizing its 2030 Vision: "Contributing to the well-being of women around the world," "Entering the global market from Toyama, the home of medicine," and "Integrating the world's happiest company with social contribution" as the desired state 10 years from now. Under this medium-term management plan, themed "Fujiらしくをあたらしく," the Group is pursuing a growth strategy toward 2030 by strengthening its core areas of women's healthcare and acute care, actively entering overseas markets such as ASEAN and North America with a sense of urgency, and enhancing its pipeline of new drugs, biosimilars, and generics so that it can expand further over the following five years.」

「A five-year medium-term management plan ending in the fiscal year ending September 2024, titled "Fujiらしくをあたらしく," was established.」

「Based on the five-year medium-term management plan "Fuji Pharma Branding" beginning in the fiscal year ended September 2015, the Fuji Pharma Group pursued strategies including the development of branded drugs and the strengthening of overseas operations. As a result, the Group achieved certain results, including the development of branded drugs licensed from Mithra and Besins Healthcare in Europe and the expansion of the business of its subsidiary OLIC(Thailand)Limited.」

「Under these circumstances, the Fuji Pharma Group has adopted "Fuji Pharma Branding" as its theme, pursuing a distinctive, high-value-added pharmaceutical business from a global perspective and building trust, empathy, and affinity among people involved in healthcare and those who aspire to good health, thereby further realizing the Fuji Pharma Group's management principles of "Growth" and "Contribution."」

「Under these circumstances, the Fuji Pharma Group has adopted "Fuji Pharma Branding" as its theme, pursuing a distinctive, high-value-added pharmaceutical business from a global perspective and building trust, empathy, and affinity among people involved in healthcare and those who aspire to good health.」

「Under these circumstances, the Fuji Pharma Group has adopted "Fuji Pharma Branding" as its theme, pursuing a distinctive, high-value-added pharmaceutical business from a global perspective and building trust, empathy, and affinity among people involved in healthcare and those who aspire to good health, thereby further realizing the Fuji Pharma Group's management principles of "Growth" and "Contribution."」

「Under these circumstances, the Fuji Pharma Group has adopted "Fuji Pharma Branding" as its theme, pursuing a distinctive, high-value-added pharmaceutical business from a global perspective and building trust, empathy, and affinity among people involved in healthcare and those who aspire to good health, thereby further realizing the Fuji Pharma Group's management principles of "Growth" and "Contribution."」

「Under these circumstances, the Fuji Pharma Group has adopted "Fuji Pharma Branding" as its theme, pursuing a distinctive, high-value-added pharmaceutical business from a global perspective and building trust, empathy, and affinity among people involved in healthcare and those who aspire to good health, thereby further realizing the Fuji Pharma Group's management principles of "Growth" and "Contribution."」

「The Fuji Pharma Group's theme is "Fuji Pharma Branding." From a global perspective, we are pursuing a distinctive, high-value-added pharmaceutical business and building trust, empathy, and affinity among people involved in healthcare and those who aspire to good health.」

「The Fuji Pharma Group has adopted "Fuji Pharma Branding" as the theme of its medium-term management plan and is pursuing the initiatives described below.」

「Under these circumstances, the Fuji Pharma Group has adopted "Fuji Pharma Branding" as its theme, pursuing a distinctive, high-value-added pharmaceutical business from a global perspective and building trust, empathy, and affinity among people involved in healthcare and those who aspire to good health, thereby further realizing the Fuji Pharma Group's management principles of "Growth" and "Contribution."」

「Under these circumstances, the Fuji Pharma Group has adopted "Fuji Pharma Branding" as its theme, pursuing a distinctive, high-value-added pharmaceutical business from a global perspective and building trust, empathy, and affinity among people involved in healthcare and those who aspire to good health, thereby further realizing the Fuji Pharma Group's management principles of "Growth" and "Contribution."」

「Under these circumstances, the Fuji Pharma Group has adopted "Fuji Pharma Branding" as its theme, pursuing a distinctive, high-value-added pharmaceutical business from a global perspective and building trust, empathy, and affinity among people involved in healthcare and those who aspire to good health, thereby further realizing the Fuji Pharma Group's management principles of "Growth" and "Contribution."」

「The Fuji Pharma Group's theme is "Fuji Pharma Branding." From a global perspective, we are pursuing a distinctive, high-value-added pharmaceutical business and building trust, empathy, and affinity among people involved in healthcare and those who aspire to good health.」